Table 1.
Characteristics of the observational studies included in the systematic review with meta-analysis
| First author name | Country | Gender | Year | Sample size | Age | Treatment | Dose | Measure | Lean mass (kg) | App. lean mass (kg) | Method of BC assay | Pre-DAS-28 | Post-DAS-28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tournadre [23] | France | M/F | 2017 | 21 | 57.8 ± 10.5 |
Tocilizumab 12 months |
NI |
Lean mass App. lean mass |
Baseline: 42.1 (± 11.1) Final: 43.2 (±11.3) |
Baseline: 17.7 (± 5.4) Final: 18.7 (± 5.6) |
DEXA | 4.94 ± 1.25 | 2.8 ± 1.5 |
| Toussirot [22] | France | M/F | 2020 | 107 | 56.6 ± 13.5 |
Tocilizumab 12 months |
8 mg/kg (monthly) | Lean mass |
Baseline: 40.76 (± 8.4) Final: 42.11 (± 8.9) |
– | DEXA | 4.93 ± 1.3 | 2.3 ± 1.3 |
| Ferraz-Amaro [24] | Spain | M/F | 2011 | 16 | 50.8 ± 14.6 |
Anti-TNF 12 months |
Varied | Lean mass |
Baseline: 53.7 (NI) Final: 50.5 (NI) |
– | BIA | 5.58 ± 0.87 | 2.89 ± 1.37 |
| Metsios [25] | United Kingdom | M/F | 2007 | 20 | 61.1 ± 6.8 |
Anti-TNF 3 months |
NI | Lean mass |
Baseline: 50.9 (± 12.7) Final: 51.1 (± 12.5) |
– | BIA | 5.66 ± 0.7 | 3.59 ± 0.7 |
| Chikugo [26] | Japan | F | 2018 | 4 | 55.3 ± 19.5 |
Tofacitinib 6 months |
NI | App. lean mass | – |
Baseline: NI Final: 20.4 (± 4.0) |
BIA | 5.1 ± 0.8 | NI |
| Al Khayyat [27] | Italy | F | 2021 | 20 | 65 ± 12.9 |
Rituximab 18 months |
Eight infusions of 500 mg~1 g |
Lean mass App. lean mass |
Baseline: 39.94 ± 8.74 Final: 38.64 ± 8.19 |
Baseline: 16.21 ± 3.60 Final: 17.84 ± 4.03 |
DEXA | NI | NI |
| Vial [28] | France | Male/Female | 2021 | 83 | 58.5 ± 10.8 | Biologic DMARD (TNFi and non-TNFi) | NI | Lean mass |
TNFi Baseline: 49.6 ± 10.8 Final: 50.7 ± 11.3 Non TNFi Baseline: 47.7 ± 11.0 Final: 47.4 ± 10.9 |
– | DEXA | 4.21 ± 1.1 | NI |
BIA bioimpedance, DEXA dual-energy X-ray absorptiometry, NI not informed, TNF tumor necrosis factor, TNFi TNF inhibitor, BC body composition, M male, F female